See schedule

10 MAY 2017


Directors: Rui Maio | Tânia Rodrigues | Pedro Pinto Marques



Pancreatic cancer is currently the fourth leading cause of cancer-related death, but its incidence has increased so much that it is expected to be the second leading cause of death by 2030, immediately behind lung cancer. 

Surgery is currently the only potentially curative therapeutic option. However, at the time of diagnosis, only about 20% of tumors are considered resectable. A better understanding of tumor biology, early diagnosis, and use of neoadjuvant therapy, are ways to change this scenario.
Surgical outcomes (particularly in terms of complications, hospitalization time, postoperative morbidity and mortality), rate of survival and utilized resources are closely related to volume, so treatment of these patients is only recommended in specialized centers that perform at least 20 pancreatic resections per year.

The Pancreatic Cancer session addresses the most current topics related to this pathology:

  • Understanding of tumor biology and diagnosis and therapeutic orientation of premalignant lesions
  • Personalized therapy in pancreatic cancer
  • How to improve results in resectable pancreatic cancer
  • What are the challenges in the treatment of advanced pancreatic cancer
  • What is the state of the art in pancreatic surgery

These topics will be presented and discussed by a panel of national and foreign specialists with a recognized reputation in the treatment of this disease.